Skip to main navigation Skip to search Skip to main content

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts

  • Kendra A. Porath
  • , Michael S. Regan
  • , Jessica I. Griffith
  • , Sonia Jain
  • , Sylwia A. Stopka
  • , Danielle M. Burgenske
  • , Katrina K. Bakken
  • , Brett L. Carlson
  • , Paul A. Decker
  • , Rachael A. Vaubel
  • , Sonja Dragojevic
  • , Ann C. Mladek
  • , Margaret A. Connors
  • , Zeng Hu
  • , Lihong He
  • , Gaspar J. Kitange
  • , Shiv K. Gupta
  • , Thomas M. Feldsien
  • , Didier R. Lefebvre
  • , Nathalie Y.R. Agar
  • Jeanette E. Eckel-Passow, Edward B. Reilly, William F. Elmquist, Jann N. Sarkaria

Research output: Contribution to journal › Article › peer-review

Abstract

Background: EGFR targeting antibody-drug conjugates (ADCs) are highly effective against EGFR-amplified tumors, but poor distribution across the blood-brain barrier (BBB) limits their efficacy in glioblastoma (GBM) when administered systemically. We studied whether convection-enhanced delivery (CED) can be used to safely infuse ADCs into orthotopic patient-derived xenograft (PDX) models of EGFRvIII mutant GBM. Methods: The efficacy of the EGFR-targeted ADCs depatuxizumab mafodotin (Depatux-M) and Serclutamab talirine (Ser-T) was evaluated in vitro and in vivo. CED was performed in nontumor and tumor-bearing mice. Immunostaining was used to evaluate ADC distribution, pharmacodynamic effects, and normal cell toxicity. Results: Dose-finding studies in orthotopic GBM6 identified single infusion of 2 μg Ser-T and 60 μg Depatux-M as safe and effective associated with extended survival prolongation (>300 days and 95 days, respectively). However, with serial infusions every 21 days, four Ser-T doses controlled tumor growth but was associated with lethal toxicity approximately 7 days after the final infusion. Limiting dosing to two infusions in GBM108 provided profound median survival extension of over 200 days. In contrast, four Depatux-M CED doses were well tolerated and significantly extended survival in both GBM6 (158 days) and GBM108 (310 days). In a toxicity analysis, Ser-T resulted in a profound loss in NeuN+ cells and markedly elevated GFAP staining, while Depatux-M was associated only with modest elevation in GFAP staining. Conclusion: CED of Depatux-M is well tolerated and results in extended survival in orthotopic GBM PDXs. In contrast, CED of Ser-T was associated with a much narrower therapeutic window.

Original languageEnglish (US)
Article numbervdac130
JournalNeuro-Oncology Advances
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Depatux-M
  • Serclutamab talirine
  • antibody-drug conjugate
  • convection-enhanced delivery
  • glioblastoma

Fingerprint

Dive into the research topics of 'Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts'. Together they form a unique fingerprint.

Cite this